Sentiment-Signal
27,4
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Tango Therapeutics, Inc. |
|---|---|
| Ticker | TNGX |
| CIK | 0001819133 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,72 Mrd. USD |
| Beta | 1,32 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 62,384,000 | -101,594,000 | -0.87 | 398,690,000 | 346,179,000 |
| 2025-09-30 | 10-Q | 53,811,000 | 15,884,000 | 0.13 | 210,136,000 | 160,031,000 |
| 2025-06-30 | 10-Q | 3,181,000 | -38,853,000 | -0.35 | 237,890,000 | 134,954,000 |
| 2025-03-31 | 10-Q | 5,392,000 | -39,876,000 | -0.36 | 274,306,000 | 166,756,000 |
| 2024-12-31 | 10-K | 42,069,000 | -130,302,000 | -1.19 | 316,492,000 | 199,517,000 |
| 2024-09-30 | 10-Q | 11,607,000 | -29,167,000 | -0.27 | 352,415,000 | 229,170,000 |
| 2024-06-30 | 10-Q | 19,875,000 | -25,551,000 | -0.24 | 381,453,000 | 247,673,000 |
| 2024-03-31 | 10-Q | 6,471,000 | -37,914,000 | -0.35 | 406,222,000 | 264,452,000 |
| 2023-12-31 | 10-K | 36,527,000 | -101,744,000 | -1.08 | 402,567,000 | 253,108,000 |
| 2023-09-30 | 10-Q | 10,732,000 | -22,263,000 | -0.23 | 428,189,000 | 276,595,000 |
| 2023-06-30 | 10-Q | 14,598,000 | -20,710,000 | -0.23 | 379,328,000 | 212,945,000 |
| 2023-03-31 | 10-Q | 5,766,000 | -28,008,000 | -0.32 | 403,773,000 | 227,264,000 |
| 2022-12-31 | 10-K | 24,860,000 | -108,176,000 | -1.23 | 436,470,000 | 249,476,000 |
| 2022-09-30 | 10-Q | 6,920,000 | -29,050,000 | -0.33 | 464,156,000 | 273,072,000 |
| 2022-06-30 | 10-Q | 5,771,000 | -24,858,000 | -0.28 | 448,399,000 | 298,704,000 |
| 2022-03-31 | 10-Q | 5,758,000 | -25,208,000 | -0.29 | 471,525,000 | 320,356,000 |
| 2021-12-31 | 10-K | 37,042,000 | -58,235,000 | -0.94 | 500,155,000 | 344,747,000 |
| 2021-09-30 | 10-Q | 6,787,000 | -19,590,000 | -0.28 | 530,137,000 | 365,413,000 |
| 2021-06-30 | 10-Q | 18,153,000 | -4,493,000 | -0.09 | 167,549,316 | 54,891,000 |
| 2021-03-31 | 10-Q | 6,386,000 | -12,106,000 | 168,260,672 | 57,891,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Crystal Adam | Officer, President, R&D | Open Market Sale | -38,460 | 25.00 | -961,500.00 | -52,2% | |
| 2026-04-01 | Crystal Adam | Officer, President, R&D | Open Market Sale | -27,000 | 21.20 | -572,478.30 | -31,1% | |
| 2026-03-25 | Crystal Adam | Officer, President, R&D | Open Market Sale | -12,000 | 20.11 | -241,320.00 | -13,1% | |
| 2026-03-05 | Crystal Adam | Officer, President, R&D | Open Market Sale | -20,251 | 15.00 | -303,765.00 | -16,5% | |
| 2026-02-25 | Crystal Adam | Officer, President, R&D | Open Market Sale | -54,345 | 12.77 | -694,208.46 | -37,7% | |
| 2026-02-03 | Beckman Daniella | Officer, Chief Financial Officer | Open Market Sale | -10,204 | 12.26 | -125,073.49 | -6,8% | |
| 2026-02-03 | Beckman Daniella | Officer, Chief Financial Officer | Open Market Sale | -113 | 12.90 | -1,457.37 | -0,1% | |
| 2026-02-03 | Crystal Adam | Officer, President, R&D | Open Market Sale | -201 | 12.90 | -2,592.32 | -0,1% | |
| 2026-02-03 | Crystal Adam | Officer, President, R&D | Open Market Sale | -18,251 | 12.26 | -223,707.98 | -12,1% | |
| 2025-10-23 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -477,401 | 10.15 | -4,846,574.95 | -263,1% | |
| 2025-09-25 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -500,000 | 8.02 | -4,008,500.00 | -217,6% | |
| 2025-09-16 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -363,541 | 7.04 | -2,559,328.64 | -138,9% | |
| 2025-09-08 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -86,459 | 7.04 | -608,628.13 | -33,0% | |
| 2025-09-05 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -642,906 | 7.00 | -4,500,342.00 | -244,3% | |
| 2025-08-22 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -302,194 | 7.00 | -2,115,358.00 | -114,8% | |
| 2025-08-19 | Third Rock Ventures IV, L.P. | 10% Owner | Open Market Sale | -1,100,000 | 7.01 | -7,712,760.00 | -418,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.